335 related articles for article (PubMed ID: 33469975)
1. Letermovir prophylaxis in solid organ transplant-Assessing CMV breakthrough and tacrolimus drug interaction.
Winstead RJ; Kumar D; Brown A; Yakubu I; Song C; Thacker L; Gupta G
Transpl Infect Dis; 2021 Aug; 23(4):e13570. PubMed ID: 33469975
[TBL] [Abstract][Full Text] [Related]
2. Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients.
Saltiel G; Faure E; Assaf A; Chopin MC; Moreau F; Faure K; Goeminne C; Vuotto F
Clin Transplant; 2024 May; 38(5):e15327. PubMed ID: 38686437
[TBL] [Abstract][Full Text] [Related]
3. Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity.
Jorgenson MR; Kleiboeker H; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
Transpl Infect Dis; 2022 Feb; 24(1):e13766. PubMed ID: 34799964
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis.
Saullo JL; Baker AW; Snyder LD; Reynolds JM; Zaffiri L; Eichenberger EM; Ferrari A; Steinbrink JM; Maziarz EK; Bacchus M; Berry H; Kakoullis SA; Wolfe CR
J Heart Lung Transplant; 2022 Apr; 41(4):508-515. PubMed ID: 35031206
[TBL] [Abstract][Full Text] [Related]
5. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
Limaye AP; Budde K; Humar A; Vincenti F; Kuypers DRJ; Carroll RP; Stauffer N; Murata Y; Strizki JM; Teal VL; Gilbert CL; Haber BA
JAMA; 2023 Jul; 330(1):33-42. PubMed ID: 37279999
[TBL] [Abstract][Full Text] [Related]
6. Use of Letermovir for Primary and Secondary Cytomegalovirus Prophylaxis in Abdominal Organ Transplantation: A Single Center Experience.
Ibrahim D; Byrns J; Maziarz E; Alexander BD; Saullo JL
J Pharm Pract; 2024 Jun; 37(3):770-779. PubMed ID: 37280011
[No Abstract] [Full Text] [Related]
7. The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients.
Jorgenson MR; Descourouez JL; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
Transpl Infect Dis; 2021 Aug; 23(4):e13693. PubMed ID: 34309158
[TBL] [Abstract][Full Text] [Related]
8. Letermovir for cytomegalovirus prophylaxis in high-risk heart transplant recipients.
Golob S; Batra J; DeFilippis EM; Uriel M; Carey M; Gaine M; Mabasa A; Fried J; Raikelkar J; Restaino S; Hi Lee S; Latif F; Yuzefpolskaya M; Colombo PC; Choe J; Majure D; Jennings D; Pereira MR; Clerkin K; Sayer G; Uriel N
Clin Transplant; 2022 Dec; 36(12):e14808. PubMed ID: 36086937
[TBL] [Abstract][Full Text] [Related]
9. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
[TBL] [Abstract][Full Text] [Related]
10. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.
Hofmann E; Sidler D; Dahdal S; Bittel P; Suter-Riniker F; Manuel O; Walti LN; Hirzel C
Transpl Infect Dis; 2021 Jun; 23(3):e13515. PubMed ID: 33210830
[TBL] [Abstract][Full Text] [Related]
11. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
Jung S; Michel M; Stamminger T; Michel D
BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
[TBL] [Abstract][Full Text] [Related]
12. Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients.
Royston L; Royston E; Masouridi-Levrat S; Chalandon Y; Van Delden C; Neofytos D
Immun Inflamm Dis; 2021 Sep; 9(3):771-776. PubMed ID: 33949798
[TBL] [Abstract][Full Text] [Related]
13. Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction.
Jorgenson MR; Descourouez JL; Saddler CM; Smith JA; Odorico JS; Rice JP; Mandelbrot DA
Clin Transplant; 2023 Dec; 37(12):e15142. PubMed ID: 37755141
[TBL] [Abstract][Full Text] [Related]
14. A new direction for cytomegalovirus prophylaxis among transplant recipients: Benefits and nonviral outcomes of letermovir use as primary CMV prophylaxis.
Moore WJ; Boutin CA; Tanna S
Curr Opin Infect Dis; 2023 Dec; 36(6):514-521. PubMed ID: 37773928
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus events in high-risk allogeneic hematopoietic-cell transplantation patients who received letermovir prophylaxis.
Chen K; Arbona-Haddad E; Cheng MP; McDonnell AM; Gooptu M; Orejas JL; Timblin K; Silverman E; Al-Hamed R; Soiffer RJ; Hammond SP; Marty FM
Transpl Infect Dis; 2021 Aug; 23(4):e13619. PubMed ID: 33866648
[TBL] [Abstract][Full Text] [Related]
16. Letermovir prophylaxis for cytomegalovirus in lung-transplant recipients: a comprehensive study with literature review of off-label use and real-world experiences.
Hirama T; Shundo Y; Watanabe T; Ohsumi A; Watanabe T; Okada Y
Clin Exp Med; 2024 Apr; 24(1):68. PubMed ID: 38578337
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in cytomegalovirus infection management in solid organ transplant recipients.
Grossi PA; Peghin M
Curr Opin Organ Transplant; 2024 Apr; 29(2):131-137. PubMed ID: 38288947
[TBL] [Abstract][Full Text] [Related]
18. Letermovir for Cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP).
Galaverna F; Baccelli F; Zama D; Tridello G; Masetti R; Soncini E; Mura R; Barzaghi F; Colombini A; Prunotto G; D'Amico MR; Calore E; Biffi A; Perruccio K; Gasperini P; Oltolini C; Quagliarella F; Giacomazzi A; Pagliara D; Locatelli F; Cesaro S
Bone Marrow Transplant; 2024 Apr; 59(4):505-512. PubMed ID: 38272999
[TBL] [Abstract][Full Text] [Related]
19. Effect of letermovir initiation on tacrolimus concentrations among lung transplant recipients receiving concomitant azole antifungal prophylaxis.
Goodlet KJ; Garcia R
Transpl Infect Dis; 2024 Apr; 26(2):e14267. PubMed ID: 38488776
[TBL] [Abstract][Full Text] [Related]
20. Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant.
Johnsrud JJ; Nguyen IT; Domingo W; Narasimhan B; Efron B; Brown JW
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1963-1970. PubMed ID: 32653623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
